BriaCell reports extended >18-47 months survival in Phase 2 metastatic breast cancer patients, with 9 cases surpassing 18 months.
Philadelphia and Vancouver, BC - On January 27, 2026, BriaCell Therapeutics Corp revealed encouraging Phase 2 survival data for their immunotherapies. The clinical-stage biotechnology company reported that several patients with metastatic breast cancer have exceeded the typical survival expectations, with 9 individuals surpassing the 18-month milestone in their latest evaluations. BriaCell's stock is listed under Nasdaq as BCTX, BCTXW, BCTXZ, BCTXL, and under TSX as BCT.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments